BPTH – Bio-Path Holdings Inc
Float Short %
2.4
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.15
EPS Last/This Y
2.53
EPS This/Next Y
0.17
Price
0.08
Target Price
12
Analyst Recom
Performance Q
-76.24
Relative Volume
Beta
0.19
Ticker: BPTH
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-17 | BPTH | 0.086 | N/A | N/A | 0 |
| 2025-11-18 | BPTH | 0.0897 | N/A | N/A | 0 |
| 2025-11-19 | BPTH | 0.08 | N/A | N/A | 0 |
| 2025-11-20 | BPTH | 0.073 | N/A | N/A | 0 |
| 2025-11-21 | BPTH | 0.083 | N/A | N/A | 0 |
| 2025-11-24 | BPTH | 0.09 | N/A | N/A | 0 |
| 2025-11-25 | BPTH | 0.0747 | N/A | N/A | 0 |
| 2025-11-26 | BPTH | 0.073 | N/A | N/A | 0 |
| 2025-12-01 | BPTH | 0.07 | N/A | N/A | 0 |
| 2025-12-02 | BPTH | 0.074 | N/A | N/A | 0 |
| 2025-12-03 | BPTH | 0.073 | N/A | N/A | 0 |
| 2025-12-04 | BPTH | 0.073 | N/A | N/A | 0 |
| 2025-12-05 | BPTH | 0.0847 | N/A | N/A | 0 |
| 2025-12-08 | BPTH | 0.081 | N/A | N/A | 0 |
| 2025-12-09 | BPTH | 0.073 | N/A | N/A | 0 |
| 2025-12-10 | BPTH | 0.071 | N/A | N/A | 0 |
| 2025-12-11 | BPTH | 0.0752 | N/A | N/A | 0 |
| 2025-12-12 | BPTH | 0.0751 | N/A | N/A | 0 |
| 2025-12-15 | BPTH | 0.0797 | N/A | N/A | 0 |
| 2025-12-16 | BPTH | 0.0797 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-17 | BPTH | 0.10 | 71.6 | - | -1.59 |
| 2025-11-18 | BPTH | 0.09 | 71.6 | - | -1.59 |
| 2025-11-19 | BPTH | 0.09 | 71.6 | - | -1.59 |
| 2025-11-20 | BPTH | 0.08 | 71.6 | - | -1.59 |
| 2025-11-21 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2025-11-24 | BPTH | 0.08 | 71.6 | - | -1.59 |
| 2025-11-25 | BPTH | 0.09 | 71.6 | - | -1.59 |
| 2025-11-26 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2025-12-01 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2025-12-02 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2025-12-03 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2025-12-04 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2025-12-05 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2025-12-08 | BPTH | 0.09 | 71.6 | - | -1.59 |
| 2025-12-09 | BPTH | 0.09 | 71.6 | - | -1.59 |
| 2025-12-10 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2025-12-11 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2025-12-12 | BPTH | 0.08 | 71.6 | - | -1.59 |
| 2025-12-15 | BPTH | 0.08 | 71.6 | - | -1.59 |
| 2025-12-16 | BPTH | 0.08 | 71.6 | - | -1.59 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
No data found
Last Quarter Act. EPS
-0.55
Avg. EPS Est. Current Quarter
-0.4
Avg. EPS Est. Next Quarter
-0.4
Insider Transactions
Institutional Transactions
Beta
0.19
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
32
Growth Score
19
Sentiment Score
28
Actual DrawDown %
100
Max Drawdown 5-Year %
-100
Target Price
12
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
-8.34
Average EPS Est. Cur. Y
-1.59
EPS Next Y. (Est.)
-1.42
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
Return on Equity vs Sector %
144.9
Return on Equity vs Industry %
160.1
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.2
EBIT Estimation
Bio-Path Holdings, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 10
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
stock quote shares BPTH – Bio-Path Holdings Inc Stock Price stock today
news today BPTH – Bio-Path Holdings Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch BPTH – Bio-Path Holdings Inc yahoo finance google finance
stock history BPTH – Bio-Path Holdings Inc invest stock market
stock prices BPTH premarket after hours
ticker BPTH fair value insiders trading